The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Diliman has identified potential biomarkers or signs that can help with early lung cancer detection with the support of the ...

A groundbreaking new urine test could soon help spot the early warning signs of lung cancer long before symptoms appear.

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.

Researchers from the Francis Crick Institute, UCL, Gustave Roussy and Memorial Sloan Kettering Cancer Center (MSK), have ...

The frequency of TI-CH and its effect on tumor evolution are unclear. We characterized CHIP and TI-CH in 421 patients with early-stage non–small-cell lung cancer (NSCLC) from the TRACERx study ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of ...